Find the Perfect Plan for Your Investment Journey
Latest price
52 Week Range
$26.47 - $41.61
Next Earnings Date
Apr 29 2025
Next Earnings Date
Apr 29 2025
Latest price
Market Cap | $1.66B |
EV | $1.37B |
Shares Outstanding | 57.42M |
Beta | 0.80 |
Analyst Rating | OUTPERFORM |
Analyst Target Price | $51.78 |
P/E 2025E | 9.20x |
P/Revenue 2025E | 1.97x |
Revenue | 32.80% |
EPS | 63.00% |
Operating Cash Flow | 30.70% |
Free Cash Flow | 30.60% |
Revenue | 18.30% |
EPS | 27.80% |
Operating Cash Flow | 21.10% |
Free Cash Flow | 7.70% |
Gross Margin 2025E | 77.90% |
Net Profit Margin 2025E | 22.93% |
ROE 2025E | 29.90% |
ROCE 2024 | 25.84% |
DPS 2025E | $0.00 |
Payout Ratio 2025E | 0.00% |
Div. Yield 2025E | 0.00% |
DPS Last 3Y CAGR | - |
Price
%
1M
3M
6M
1Y
3Y
5Y
Harmony Biosciences Holdings, Inc.
HRMY
Sector
Healthcare
Industry
Biotechnology
CEO
Dayno, Jeffrey
Employees
268
Website
www.harmonybiosciences.comIPO Date
2020-08-19
Headquarters
630 West Germantown Pike, Suite 215, Plymouth Meeting, Pennsylvania, 19462, United States
COMPANY
NEWSLETTER
© Copyright 2025, All Rights Reserved